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Abstract 
Background: Neoehrlichiosis is an infectious disease caused by the tick-borne bacterium “Candidatus 
Neoehrlichia mikurensis”. Splenectomy and rituximab (anti-CD20) therapy are risk factors for severe 
neoehrlichiosis, a condition characterized by fever and vascular complications such as deep vein 
thrombosis. The principal aim of this study was to examine if neoehrlichiosis patients had low levels 
of natural IgM antibodies and/or were hypogammaglobulinemic, and if such deficiencies were 
associated with asplenia and development of vascular complications. 
Methods: Neoehrlichiosis patients (n = 9) and control subjects (n = 10) were investigated for total 
serum levels of IgG, IgA, and IgM, and levels of natural IgM antibodies directed against 
pneumococcal polysaccharides (6B, 14) by ELISA and against the malondialdehyde acetaldehyde 
epitope of oxidized LDL by a chemoluminescence immunoassay. The multivariate method Projection 
to Latent Structures (PLS) was applied to examine the relationships between levels of natural IgM 
antibodies, splenectomy, and vascular complications, respectively. 
Results: Half of the neoehrlichiosis patients lacked or had very low levels of natural IgM antibodies 
directed against pneumococcal polysaccharides and malondialdehyde acetaldehyde compared with 
1/10 of the age-matched control subjects. One neoehrlichiosis patient and one control subject each 
were hypogammaglobulinemic. The levels of natural antibodies to the two pneumococcal serotypes 
were positively associated to one another, and negatively associated to the development of deep vein 
thrombosis according to the multivariate analyses. Natural IgM antibody levels were not directly 
coupled to splenectomy. 
Conclusions: Neither hypogammaglobulinemia nor depletion of natural IgM antibodies alone 
predisposes for severe neoehrlichiosis. This indicates that specific antibodies are likely to be key 
defense mechanisms in neoehrlichial infection. 
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Introduction 
Candidatus Neoehrlichia mikurensis (Ca. N. mikurensis) is an emerging tick-borne pathogen of the 
Anaplasmataceae family that can infect human beings (1-3). It gives rise to the infectious disease 
neoehrlichiosis, which in severe cases may present as a febrile illness that does not respond to broad-
spectrum antibiotics, frequently accompanied by vascular and thromboembolic complications such as 
deep vein thrombosis, pulmonary embolism, transitory ischemic attacks and arterial aneurysms (4). 
Diagnosis of this strict intracellular bacterium presently relies on PCR as it does not grow in blood 
culture flasks, nor are there any serological assays available (5). The novelty of this microbe and the 
fact that it escapes detection by routine microbiological diagnostic methods probably explains why 
there are only 30-some published cases of neoehrlichiosis worldwide despite the fact that Ca. N. 
mikurensis is widely spread among ticks and rodents in Europe and Asia (5). 
The knowledge regarding what constitutes an efficient immune response to this new pathogen is 
scant. However, most patients afflicted by the more serious variant of neoehrlichiosis have been older 
and immunocompromised (4). As a rule, the patients have had an underlying hematologic malignancy 
such as chronic lymphocytic leukemia or malignant lymphoma, and/or a systemic rheumatic or 
autoimmune disease (4). A common theme for these diseases is that they are caused by clonal 
expansion of B lymphocytes and may feature hypogammaglobulinemia and/or impaired antibody 
production either directly, or secondary to immunosuppressive therapy. In addition, a high frequency 
of neoehrlichiosis patients have been splenectomized, and/ or treated with the B cell-depleting 
monoclonal anti-CD20 antibody rituximab (4; 6). Together, this indicates that B cells and antibodies 
may be important protective immune mechanisms to combat Ca. N. mikurensis infection. 
The aim of this study was to investigate the role of natural IgM antibodies in neoehrlichiosis. 
Unfortunately, it is not possible to study anti-neoehrlichial B cell or antibody responses directly, as 
Ca. N. mikurensis has not yet been cultivated nor has its genome been sequenced. As a consequence, 
it has not been possible to set up specific ELISA, IFA or ELISPOT assays for serological analyses. 
We hypothesized that natural IgM antibodies might be an important host defense mechanism in 
neoehrlichiosis since polyreactive IgM antibodies produced by splenic B1 cells protect against murine 
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ehrlichiosis (7) and splenectomy is a risk factor for severe neoehrlichiosis. Ca. N. mikurensis is not 
believed to be encapsulated (8), implying that the importance of the spleen in neoehrlichial host 
defense does not lie in its ability to synthesize opsonizing anti-carbohydrate IgG antibodies. Natural 
IgM antibodies form a central part of innate immunity by virtue of their broad anti-microbial 
specificity (9-11). Unlike specific IgM antibody responses, the generation of natural IgM antibodies is 
not antigen-driven. In fact, natural IgM antibodies are present in cord blood. Supposedly, self-antigens 
drive their production, which explains why they also recognize stressed, damaged or dead host-derived 
cells (12; 13). Polyreactivity, i.e., the ability to bind several unrelated antigens that share epitope 
structures, is an essential feature of natural antibodies (7). 
To test whether a shortage of natural IgM antibodies is a risk factor for contracting 
neoehrlichiosis, we measured the levels of natural IgM antibodies in the sera of patients diagnosed 
with neoehrlichiosis that could bind to an epitope of oxidized LDL named malondialdehyde 
acetaldehyde (13), expressed on apoptotic eukaryotic cell surfaces, and to pneumococcal 
polysaccharides (14), expressed on bacterial cell walls, respectively. We also quantified the total 
serum levels of IgG, IgA and IgM to evaluate if neoehrlichiosis patients were 
hypogammaglobulinemic. Finally, the data were analyzed using the multivariate method of pattern 
recognition “Projection to Latent Structures” to see if an association between natural IgM levels, 
splenectomy and vascular complications could be identified. 
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Materials and methods 
Study subjects 
Nine patients diagnosed with severe Ca. N. mikurensis infection in Sweden were investigated. Eight 
of the patient cases (SE01-SE12) have been described earlier (4; 15). All patients had febrile illness. 
Clinical data are summarized in Table 1. Sera collected from ten age- and gender-matched subjects 
sent to the Clinical Microbiology Laboratory at Sahlgrenska University Hospital in Göteborg, Sweden, 
for analysis of Borrelia-specific IgM and IgG antibodies (Chemiluminescence immunoassay, Liaison, 
DiaSorin S.p.A., Saluggia, Italy) were used as controls (Table 2). Ethical permission was granted by 
the local Ethical Review Board of Göteborg, Sweden. 
 
Total IgG, IgA, and IgM in serum 
Serum immunoglobulin quantification was done by nephelometry at the accredited Laboratory of 
Clinical Immunology, Sahlgrenska University Hospital, Göteborg, Sweden. Reference values are 
based on a Swedish population. 
 
Natural IgM antibody levels to oxidized LDL epitope malondialdehyde acetaldehyde 
The LDL fraction (density 1.019–1.063g ml−1) was isolated from human plasma by sequential density-
gradient centrifugation and modified by malondialdehyde acetaldehyde (MAA) as previously 
described (16). Natural IgM to MAA in serum samples was determined by a chemiluminescence 
immunoassay. In short, antigens (5 µg ml−1) MAA-LDL, MAA-BSA (Merck, Darmstadt, Germany), 
MDA-BSA and 0.5% (w/v) fish gelatin (Sigma, St Louis, MO, USA) dissolved in 0.27 mM EDTA in 
PBS were immobilized overnight in 96-well microtiter plates at 4°C. The wells were thrice in 0.27 
mM EDTA in PBS. Nonspecific binding sites were blocked with 0.5% fish gelatin in 0.27 mM 
EDTA/PBS for 50 min at room temperature. Serum samples (1:100) were incubated for 1 h at room 
temperature. When measuring the total IgM concentration in plasma, 5 µg ml−1 of anti-human-IgM 
(Sigma) in 0.27 mM EDTA/PBS was immobilized to microtiter plates and purified human IgM 
(Sigma) was used as a standard. Serum samples from the patients and healthy controls were diluted 
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1:10 000 for determination of the total IgM concentration. Alkaline phosphatase-conjugated anti-
human IgM (Sigma) was used as a secondary antibody and LumiPhos 530 as a substrate in the assay. 
The chemiluminescence was measured as relative light units (RLU) with a Wallac Victor3 multilabel 
reader (Perkin Elmer, Waltham, MA, USA).  
 
Natural IgM antibody levels to pneumococcal polysaccharide 
Serum was assayed for IgM antibodies to pneumococcal serotypes 6B and 14 at the University 
College London Institute of Child Health’s WHO Reference Laboratory for Pneumococcal Serology, 
by adapting a previously described IgG ELISA protocol 
(http://www.vaccine.uab.edu/ELISA%20Protocol.pdf). In short, serum samples were mixed with an 
absorbent that contains C-polysaccharide and 22F capsular polysaccharide to neutralize antibody 
binding to contaminants normally present in pneumococcal polysaccharides used for coating ELISA 
plates. Bound IgM antibodies were detected with anti-human IgM goat antibody conjugated with ALP 
at 1/3000 dilution (Sigma) for 2 h, at RT, followed by the addition of substrate p-nitrophenyl 
phosphate. Absorbance was read at 405 nm and 690 nm. Antibody concentrations were extrapolated 
from double point dilutions by using a standard human anti-pneumococcal reference serum, lot 89-SF. 
 
Statistical analyses 
The non-parametric Wilcoxon signed rank test was used to compare groups with a statistical 
significance level of P <0.05, using Graph Pad Prism software 6.0 (San Diego, CA). Correlations were 
estimated by the Spearman correlation test. The multivariate method for pattern recognition 
“Projection to Latent Structures” (PLS) was applied to identify associations between levels of natural 
antibodies and other laboratory and clinical data. This technique merges features from principal 
component analysis and multiple linear regression, which can be used to identify association patterns 
between selected query variables (Y) and sets of analysis variables (X). Models can be generated to 
assess to what degree a set of variables can explain the covariance between Y-variable(s) and the 
analysis or predictor variables X (17).  
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Results 
The neoehrlichiosis patients had a mean age of 65 (range 54-78), and seven out of nine were men 
(Table 1). The majority of the patients (7/9) suffered from a vascular complication, in most of the 
cases deep vein thrombosis, and less frequently pulmonary embolism, transitory ischemic attack or 
vascular aneurysm (Table 1). All but one had received immunosuppressive therapy, including 
rituximab in one third of the cases (Table 3). More than half of the patients were asplenic, either 
following splenectomy or due to inborn splenic aplasia. Anonymous age- and gender-matched persons 
with suspected Borrelia burgdorferi s.l. infections were selected as controls (mean age 66; range 54-
79). The reasoning behind this choice of control subjects was that both Ca. N. mikurensis and Borrelia 
spp. are tick-borne bacterial species, and that the aging immune system and gender are factors that 
need to be taken into account in infectious host defense (18; 19). 
Hypogammaglobulinemia 
Since all of the neoehrlichiosis patients were immunocompromised, we first investigated if they had 
sub-normal levels of immunoglobulins (Table 3). One of the neoehrlichiosis patients (SE12) had 
serum IgG, IgA, and IgM levels below the reference interval, as did one of the control subjects 
(BO09). In addition, one of the neoerhlichiosis patients had serum IgG just below the cut-off level, but 
did not fall below the definition of IgG deficiency of < 6 g/L (Table 3). All in all, the majority of the 
neoehrlichiosis patients had normal levels of serum IgG (6/8), serum IgA (7/8) and serum IgM (8/9), 
as did the controls (9/10), for all three isotypes (Fig. 1). 
Natural IgM antibodies to pneumococci 
Analysis of natural IgM antibody levels to the pneumococcal serotypes 6B (of low antigenicity) and 
14 (of high antigenicity) revealed that half of the assayable neoehrlichiosis patients (3/6) had 
undetectable levels of serum IgM to serotypes 6B and 14, respectively (Fig. 2 and Table 3). In 
comparison, 1/10 control subjects lacked natural IgM antibodies to serotype 14 and 2/10 had 
undetectable or very low levels of IgM to serotype 6B (Fig. 2). 
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Natural IgM antibodies to malondialdehyde acetaldehyde epitope 
Half of the neoehrlichiosis patients also had markedly reduced levels of natural IgM antibodies to the 
oxidized LDL epitope malondialdehyde acetaldehyde (MAA). Hence, 4/9 assayable neoehrlichiosis 
patients had very low levels of antibodies compared with the age-matched control subjects (Fig. 3). 
Multivariate analyses 
Lastly, we examined if study subjects having high levels of natural IgM of one specificity tended to 
have high levels of the other specificities, i.e. if the levels of IgM to serotypes 6B, 14 and MAA were 
positively associated with one another. We also evaluated if the levels of natural IgM antibodies co-
varied with age, sex, splenectomy, immune suppressive therapy, rituximab therapy, 
hypogammaglobulinemia, and development of vascular complications. The multivariate method of 
pattern recognition PLS was chosen to address these questions. The parameter “Levels of natural IgM 
antibodies to pneumococcal serotype 14” was set as the query Y-variable, and its relation to the 
following X-variables was assessed: levels of natural IgM to serotype 6B, levels of natural IgM to 
serotype MAA, total levels of serum IgG, IgA, IgM, immunosuppressive therapy (yes or no), 
rituximab therapy (yes or no), having a spleen (yes or no), and development of vascular complications 
(deep vein thrombosis, pulmonary embolism and/or transitory ischemic attacks). It was found that 
natural IgM antibodies to serotype 14 were positively associated with levels of natural IgM antibodies 
to serotype 6B, and negatively associated with development of vascular complications, deep vein 
thrombosis in particular (Fig. 4A). In addition, the multivariate analysis revealed a possible positive 
association between the levels of IgM to MAA with total serum IgG levels among the neoehrlichiosis 
patients. This was partly confirmed by univariate correlation analyses. A positive association was seen 
between the levels of natural IgM to serotype 14 and 6B (Fig. 4B), but it did not quite reach statistical 
significance, most likely because of too few study subjects (n = 6). A statistically significant positive 
association was shown between the levels of natural IgM to MAA-LDL and total serum IgG (Fig. 4C). 
We could not do univariate contingency analyses of the possible inverse relationship between having 
high levels of natural IgM antibodies to serotype 14 and the risk of developing vascular complications 
because of limited number of evaluable study subjects (n = 6). Nevertheless, it may be seen that the 
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three patients with undetectable natural IgM to serotype 14 (SE02, SE10, SE12; Table 1 and 3) all had 
contracted deep vein thrombosis. These same patients also had very low levels of natural IgM to 
MAA-LDL (Table 1 and 3). 
It was not meaningful to do contingency analyses of the relationship between splenectomy and 
levels of natural IgM antibodies due to the limited number of patients. However, it was seen that out of 
the 6 neoehrlichiosis patients, 1/3 patients with high IgM levels to serotype 14 was splenectomized 
compared with 1/3 patients with low levels of antibodies to serotype 14. Similarly, half of the patients 
with high levels of antibodies to MAA were splenectomized (2/4) and half of those with low MDA 
levels were splenectomized (2/4). Together, this suggests that having or not having a spleen does not 
have a major influence on the levels of natural IgM antibodies. 
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Discussion 
The observation that splenectomy and rituximab therapy seem to be independent risk factors for the 
development of severe neoehrlichiosis (4) led us to examine the hypotheses that shortage of natural 
IgM antibodies and/or hypogammaglobulinemia might feature among patients afflicted by severe 
neoehrlichiosis. Hypogammaglobulinemia could be discarded as a major protective mechanism as 
only one of the eight neoehrlichiosis patients had clearly reduced levels of all three immunoglobulin 
isotypes. This patient had not been treated with rituximab. Rituximab is a monoclonal antibody 
directed against CD20, which is expressed on the surface of most maturational stages of B cells except 
for plasma cells. Consequently, rituximab does not deplete the body of existing long-lived antibody-
producing plasma cells, which explains why IgG deficiency only affects a fraction of rituximab-treated 
patients, roughly every third patient (20; 21). In contrast, IgM deficiency appears to be more common 
after rituximab treatment, affecting an estimated two thirds of treated patients (20). Irrespective of this, 
IgM deficiency was not prominent among the studied neoehrlichiosis patients. 
Half of the neoehrlichiosis patients lacked natural IgM antibodies. Our expectation was that all the 
patients in our cohort of immunosuppressed neoehrlichiosis patients would have been deficient in 
natural IgM antibodies since patients infected with the related pathogen Ehrlichia chaffeensis develop 
high titers of polyreactive IgM antibodies, implying that this might be a crucial immune defense 
mechanism (7). Our finding of a near-significant correlation between IgM seroreactivity to the two 
pneumococcal serotypes among the neoehrlichiosis patients might indicate polyreactivity. 
Unfortunately, we could not assess if there existed a correlation between IgM reactivity to MAA and 
pneumococcal polysaccharide due to the small number of assayable serum samples. The limited 
number of patients is one of the shortcomings of the study, although it should be emphasized that there 
are only thirty-some published cases of neoehrlichiosis worldwide. An intriguing finding was the 
apparently negative association between levels of natural IgM antibodies to pneumococcal serotype 14 
and development of vascular complications, deep vein thrombosis in particular. Clot formation is a 
primitive form of infectious defense and might reflect an inability of the host to curb the infection. 
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An interesting observation was that 3/9 neoehrlichiosis patients were diagnosed with B-cell 
lymphoproliferative non-Hodgkin lymphomas, e.g. B cell chronic lymphocytic leukemia and diffuse 
large B cell lymphoma, diseases characterized by CD5+ B cell clones with dysregulated natural IgM 
production. In fact, a majority of B-CLL patients have B cell clones that express IgM B-cell receptors 
specific for oxLDL epitopes (22-24). The clones are often frozen in an anergic, resting (G0 stage of 
cell cycle) and do not release IgM antibodies until activated by innate receptor signals such as TLR9 
ligands, which includes un-methylated bacterial CpG-rich DNA (22). However, patient SE01 
presented with extreme levels of natural IgM to the oxidized LDL epitope MAA (160 RLU x 10-3) and 
elevated total serum IgM values of 7.1 mg/ml, which might indicate that the leukemic clone secreted 
IgM anti-oxLDL appearing as an M-component. 
The spleen did not seem to be of major importance for the generation of natural IgM in this study 
cohort as shortage of natural IgM was equally frequent in the splenectomized as in the non-
splenectomized group of patients. It is far from clear where natural IgM are produced in the human 
body. In mice, B1 cells located in the spleen are the major producers of natural IgM, but other sites of 
production such as the bone marrow, body cavities and regional lymph nodes may also be engaged (9). 
The B1 subset of natural antibody-producing cells has not been defined in humans, but splenic 
marginal zone B cells have been proposed to be possible B1 counterparts: A subset of the human 
marginal zone B cells have polyreactive B cell receptors that can bind a variety of microbial structures, 
akin to the toll-like receptors and generate T cell independent antibody responses (25). Moreover, 
DiGeorge patients have with pulp atrophy of the spleen and decreased levels of marginal zone-like B 
cells in the circulation together with reduced levels of natural IgM antibodies (26). 
Altogether, our results suggest that asplenia probably constitutes a risk factor for neoehrlichiosis 
patients because the spleen is where specific IgM and IgG memory B cells are located (27; 28), rather 
than where natural IgM antibodies are produced. Severe neoehrlichiosis has only been described in 
older patients with underlying systemic rheumatic or hematologic disease, not in persons 
splenectomized because of trauma, and it is the former group of patients that appears unable to 
compensate for the removal of the spleen by establishing memory B cells in other body sites (29). 
Similarly, rituximab therapy has a dramatic effect on the levels of circulating memory B cells, which 
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recover much more slowly, if at all, after termination of therapy compared with naïve B cells (30). 
Hopefully, we will be able to test the hypothesis that loss of specific IgM memory B cells is a crucial 
risk factor for severe neoehrlichiosis in the near future using specific immune assays once bacterial 
antigens or cultivated bacterial are available. 
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Table 1. Clinical data of neoehrlichiosis patients 
Patient 
ID 
Sex Age Diagnosis Vascular 
complication 
SE01 Male 77 B-Chronic lymphocytic leukemia DVT, PE, TIA 
SE02 Male 75 B-Chronic lymphocytic leukemia DVT 
SE03 Female 67 Systemic lupus erythematosus TIA 
SE05 Male 54 Hereditary gout, psoriasis Aneurysm 
SE06 Male 59 Diffuse large B cell lymphoma None 
SE09 Male 78 Rheumatoid arthritis None 
SE10 Male 55 Granulomatosis with polyangiitis DVT 
SE12 Male 57 Pre-B-Acute lymphocytic leukemia DVT 
SE13 Female 65 Autoimmune hemolytic anemia DVT, PE 
DVT = Deep vein thrombosis; PE = Pulmonary embolism; TIA = transitory ischemic attacks. 
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Table 2. Control subjects 
ID Sex Age Serum antibodies to Borrelia 
(AU/mL) 
   IgM (Ref <25) IgG ( Ref <15) 
BO01 Male 54 7.6 <5 
BO02 Male 54 15 1012 
BO03 Male 58 <2 <5 
BO04 Male 60 14 954 
BO05 Male 71 16 12 
BO06 Male 72 9.6 50 
BO07 Male 79 2.6 <5 
BO08 Male 74 <2 874 
BO09 Female 67 11 <5 
BO10 Female 67 11 39 
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Table 3. Serum levels of natural IgM Abs in neoehrlichiosis patients in 
relation to asplenia and immunosuppressive therapy 
Patient 
ID 
Immunosuppression Total serum Pneumococcal 
serotype 
Oxidized 
LDL epitope 
 Splen-
ectomy 
Rituxa ISb IgM* 
mg/mL 
IgG 
mg/mL 
6B 
µg/mL 
14 
µg/mL 
MAAc 
RLUdx10-3 
SE01 Yes No Yes 7.1 10 NAe NA 160 
SE02 Yes No Yes 1.9 7.5 <0.15 <0.15 3.5 
SE03 Yes No No 1.2 14 NA NA 16 
SE05 No No Yes 1.0 19 0.78 0.52 16 
SE06 Yes Yes Yes 0.50 NA NA NA 8.6 
SE09 No Yes Yes 0.41 8 0.48 1.1 3.0 
SE10 No Yes Yes 0.45 6.5 <0.15 <0.15 5.1 
SE12 No No Yes 0.27 3.0 <0.15 <0.15 0.69 
SE13 Yes No Yes 0.96 8.4 1.1 0.68 15 
a) Rituximab therapy 
b) Any type of immunosuppressive therapy 
c) MAA, malondialdehyde acetaldehyde 
d) RLU, relative light units 
e) NA, not assessed 
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Figure 1 
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Fig. 1 Total serum IgG, IgA, and IgM levels among neoehrlichiosis patients and control subjects. 
Each symbol denotes one individual. Horizontal bars indicate medians. Dashed line shows lower 
reference value for serum IgG (6.7 g/L), IgA (0.88 g/L) and IgM (0.27 g/L), respectively. The Mann-
Whitney test was used for statistical comparisons. 
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Figure 2 
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Fig. 2 Levels of natural IgM antibodies to pneumococcal polysaccharides among neoehrlichiosis 
patients and control subjects. Each symbol denotes serum IgM level to the indicated pneumococcal 
serotype derived from one individual. Horizontal bars indicate medians. Dashed line shows the 
detection limit of IgM antibodies = 0.15 µg/mL. The Mann-Whitney test was used for statistical 
comparisons. 
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Figure 3 
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Fig. 3 Serum levels of natural IgM antibodies to the oxidized LDL epitope malondialdehyde 
acetaldehyde (MAA) in patients with neoehrlichiosis and healthy controls. Natural anti-MAA IgM 
antibodies in serum samples of neoehrlichiosis patients (n = 9) and age- and gender-matched controls 
(n = 10) were determined by a chemiluminescence-based immunoassay and expressed as “Relative 
light units” (RLU). Horizontal bars indicate medians. (P = 0.24; Mann-Whitney test). 
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Figure 4 
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Fig 4. The levels of natural IgM antibodies to pneumococcal serotype 14 are positively associated 
with natural IgM antibody levels to serotype 6, and negatively associated to occurrence of deep 
vein thrombosis in patients with neoehrlichiosis. (A) The multivariate method of pattern recognition 
Projection to Latent Structures (PLS) was employed. The selected Y-variable was “levels of natural 
IgM to pneumococcal serotype 14”, indicated by a triangle labelled “14”. The analyzed X-variables 
were deep vein thrombosis (DVT), levels of natural IgM antibodies to malondialdehyde acetaldehyde 
(MAA), male sex, immunosuppressive therapy (IS), transitory ischemic attacks (TIA), total serum 
IgM levels (IgM), having a spleen (spleen), total serum levels of IgG, IgA, and IgM, pulmonary 
embolism (PE), age, rituximab therapy (Ritux), and levels of natural IgM antibodies to pneumococcal 
serotype 6B (6B). Parameters that are closely located to the Y-variable in the graph are positively 
associated with the Y-variable, whereas variables that are distant from the category marker along the 
diagonal line are negatively associated with the Y-variable. The quality of the generated model is 
indicated by R2Y, which estimates the amount of variance in Y that is explained by the X-variables 
(0.97) and the validity of the model is indicated by the Q2Y-value (0.61). PC(1) and PC(2) indicates 
that the model is composed of two principal components (B) Correlation between natural IgM levels 
to serotype 14 and serotype 6B in neoehrlichiosis patients (n =6). (C) Correlation between total serum 
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IgG and levels of natural IgM against malonacetate aldehyde-LDL in neoehrlichiosis patients 
combined (n = 9). r = Spearman correlation coefficient. 
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